CN117355331A - 抗Siglec组合物及其用途 - Google Patents

抗Siglec组合物及其用途 Download PDF

Info

Publication number
CN117355331A
CN117355331A CN202280031124.9A CN202280031124A CN117355331A CN 117355331 A CN117355331 A CN 117355331A CN 202280031124 A CN202280031124 A CN 202280031124A CN 117355331 A CN117355331 A CN 117355331A
Authority
CN
China
Prior art keywords
ser
cancer
siglec
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280031124.9A
Other languages
English (en)
Chinese (zh)
Inventor
Y·刘
P·郑
M·戴文波特
刘明月
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onco Pharmaceuticals
University of Maryland, Baltimore
Original Assignee
Onco Pharmaceuticals
University of Maryland, Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onco Pharmaceuticals, University of Maryland, Baltimore filed Critical Onco Pharmaceuticals
Publication of CN117355331A publication Critical patent/CN117355331A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280031124.9A 2021-04-30 2022-04-29 抗Siglec组合物及其用途 Pending CN117355331A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182271P 2021-04-30 2021-04-30
US63/182,271 2021-04-30
PCT/US2022/027006 WO2022232558A1 (en) 2021-04-30 2022-04-29 Anti-siglec compositions and uses thereof

Publications (1)

Publication Number Publication Date
CN117355331A true CN117355331A (zh) 2024-01-05

Family

ID=83848703

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280031124.9A Pending CN117355331A (zh) 2021-04-30 2022-04-29 抗Siglec组合物及其用途

Country Status (10)

Country Link
US (1) US20240218067A1 (enExample)
EP (1) EP4329806A4 (enExample)
JP (1) JP2024515879A (enExample)
KR (1) KR20240006519A (enExample)
CN (1) CN117355331A (enExample)
AU (1) AU2022267362A1 (enExample)
CA (1) CA3216324A1 (enExample)
IL (1) IL308137A (enExample)
MX (1) MX2023012759A (enExample)
WO (1) WO2022232558A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117643575A (zh) * 2023-11-03 2024-03-05 中山大学 一种纳米材料及其制备方法和应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026055671A1 (en) * 2024-09-09 2026-03-12 OncoC4, Inc. Anti-siglec compositions and uses thereof for treating neurodegenerative diseases
CN120459278A (zh) * 2025-07-14 2025-08-12 南京医科大学 Siglec-10/G或包含Siglec-10/G蛋白结构的融合蛋白在制备治疗胶质瘤药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120171114A1 (en) * 2008-04-11 2012-07-05 Haeuw Jean-Francois Anti-cd151 antibodies and their use in the treatment of cancer
US8163281B2 (en) * 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
WO2015107171A1 (en) * 2014-01-17 2015-07-23 Sanofi Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-fgfr4 antibody
AU2016354924A1 (en) * 2015-11-17 2018-06-21 Innate Pharma Siglec-10 antibodies
WO2020198353A1 (en) * 2019-03-26 2020-10-01 Forty Seven, Inc. Multispecific agents for treatment of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117643575A (zh) * 2023-11-03 2024-03-05 中山大学 一种纳米材料及其制备方法和应用

Also Published As

Publication number Publication date
AU2022267362A1 (en) 2023-11-09
IL308137A (en) 2023-12-01
JP2024515879A (ja) 2024-04-10
EP4329806A1 (en) 2024-03-06
MX2023012759A (es) 2023-11-13
WO2022232558A1 (en) 2022-11-03
CA3216324A1 (en) 2022-11-03
US20240218067A1 (en) 2024-07-04
EP4329806A4 (en) 2025-09-17
TW202305005A (zh) 2023-02-01
AU2022267362A9 (en) 2023-11-16
KR20240006519A (ko) 2024-01-15

Similar Documents

Publication Publication Date Title
KR102584675B1 (ko) GUCY2c에 특이적인 항체 및 이의 용도
KR102461228B1 (ko) Tigit-결합제를 포함하는 암 치료 방법
TWI870335B (zh) 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
US20250043003A1 (en) Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
KR102608723B1 (ko) 항―ｐｄ－１ 항체 및 그의 용도
TW201705981A (zh) 治療組合及治療贅瘤之方法
JP2022525071A (ja) Ｃｔｌａ－４遮断剤とｐｄ－１遮断剤とを含む抗癌併用療法
CN114901306A (zh) 用于治疗癌症的疗法
CN112839962A (zh) 用于治疗癌症的抗mertk抗体
US20240218067A1 (en) Anti-siglec compositions and uses thereof
AU2021311701A1 (en) Anti-CTLA-4 antibody and use thereof
US20210355220A1 (en) Antibodies specific to ctla-4 and uses thereof
CN114630679A (zh) 抗garp抗体和免疫调节剂的组合
EP4494655A1 (en) Combination of multi-specific molecule and immune checkpoint inhibitor
EA049996B1 (ru) Антитело к siglec-10 (варианты)
HK40115416A (en) Combination of multi-specific molecule and immune checkpoint inhibitor
HK40124330A (en) Anti-cd39 antibodies and use thereof
HK40124330B (en) Anti-cd39 antibodies and use thereof
HK40089230A (en) Pharmaceutical composition and use
HK40113788A (en) Anti-cd39 antibodies and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination